Journal of Cardiovascular Computed Tomography最新文献

英文中文

Correlation Between Trabecular Attenuation, Coronary Artery Calcium Score, and Aortic Valve Calcium Score in Tavi Patients: A Retrospective Analysis

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.051

J. Niemierko, K. Sienkiewicz, J. Fijalkowska

引用次数: 0

Evaluating Coronary Hemodynamics: Comparision of Calcium Removal Algorithm and Standard Reconstruction Using Photon-counting Ct

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.016

B. Sipos , Z. Jokkel , B. Vattay , M. Boussoussou , M. Vecsey-Nagy , M. Kolossváry , D. Juhász , P. Maurovich-Horvat , B. Szilveszter

引用次数: 0

Prognostic value of left ventricular mass measured on coronary computed tomography angiography 冠状动脉计算机断层扫描血管造影测量的左心室质量的预后价值。

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.10.010

Michael Abiragi, Melanie Chen, Billy Lin, Heidi Gransar, Damini Dey, Piotr Slomka, Sean W. Hayes, Louise E. Thomson, John D. Friedman, Daniel S. Berman , Donghee Han

Background

Left ventricular (LV) mass is a well-established prognostic indicator for cardiovascular risk. Measurement of LV mass on coronary computed tomography angiography (CCTA) is considered optional. We aimed to assess for associations between LV mass measured on CCTA with all-cause mortality (ACM) risk and to determine age- and sex-specific distributions.

Methods

We evaluated patients without known coronary artery disease (CAD) who underwent CCTA at a single center. We assessed age- and sex-specific distributions (10th, 25th, 50th, 75th, and 90th percentiles) of LV mass index. ACM, the primary endpoint, was recorded over a median period of 5.1 [interquartile range: 1.4–8.4] years. The association between LV mass and mortality risk was assessed using multivariable Cox models adjusted for age, sex, medical history, coronary artery calcium (CAC) score and CCTA stenosis.

Results

4187 patients (mean age: 61.9 ± 11.7, 63 % male) were included. Male sex, African American ethnicity, Hypertension, CAC>400, and smoking were independent predictors of increased LV mass index. During the median 5.1 years of study follow, 265 (6.3 %) deaths occurred. Increased LV mass index percentiles were associated with increased risk of ACM. The addition of LV mass index percentiles improved discrimination and reclassification for mortality prediction over a model with age, sex, conventional risk factors, CAC score and CCTA stenosis severity (X² improvement: 22.68, NRI: 28 %, both p < 0.001).

Conclusion

In a large sample of patients without known CAD who underwent CCTA, increased LV mass index provided independent and incremental prognostic value for all-cause mortality. Assessment of LV mass by CCTA, considering age and gender distribution, can be utilized clinically to identify patients with high myocardial mass.

背景：左心室（LV）质量是一项公认的心血管风险预后指标。冠状动脉计算机断层扫描血管造影术（CCTA）可选择测量左心室质量。我们的目的是评估 CCTA 测量的左心室质量与全因死亡率（ACM）风险之间的关联，并确定年龄和性别特异性分布：我们评估了在一个中心接受 CCTA 检查的无已知冠状动脉疾病（CAD）的患者。我们评估了左心室质量指数的年龄和性别特异性分布（第 10、25、50、75 和 90 百分位数）。主要终点 ACM 的记录时间中位数为 5.1 年[四分位间范围：1.4-8.4]。采用多变量 Cox 模型评估左心室质量与死亡风险之间的关系，并对年龄、性别、病史、冠状动脉钙化（CAC）评分和 CCTA 狭窄程度进行调整：共纳入 4187 名患者（平均年龄：61.9 ± 11.7，男性占 63%）。男性、非裔美国人、高血压、CAC>400 和吸烟是左心室质量指数增加的独立预测因素。在中位 5.1 年的随访期间，共有 265 人（6.3%）死亡。左心室质量指数百分位数增加与 ACM 风险增加有关。与包含年龄、性别、常规风险因素、CAC 评分和 CCTA 狭窄严重程度的模型相比，增加左心室质量指数百分位数提高了死亡率预测的分辨力和再分类能力（X2 改善：22.68，NRI：28%，均为 p 结论：在接受 CCTA 检查的无已知 CAD 的大样本患者中，左心室质量指数的增加对全因死亡率具有独立的增量预后价值。考虑到年龄和性别分布，CCTA 对左心室质量的评估可用于临床，以识别心肌质量高的患者。

{"title":"Prognostic value of left ventricular mass measured on coronary computed tomography angiography","authors":"Michael Abiragi, Melanie Chen, Billy Lin, Heidi Gransar, Damini Dey, Piotr Slomka, Sean W. Hayes, Louise E. Thomson, John D. Friedman, Daniel S. Berman , Donghee Han","doi":"10.1016/j.jcct.2024.10.010","DOIUrl":"10.1016/j.jcct.2024.10.010","url":null,"abstract":"<div><h3>Background</h3><div>Left ventricular (LV) mass is a well-established prognostic indicator for cardiovascular risk. Measurement of LV mass on coronary computed tomography angiography (CCTA) is considered optional. We aimed to assess for associations between LV mass measured on CCTA with all-cause mortality (ACM) risk and to determine age- and sex-specific distributions.</div></div><div><h3>Methods</h3><div>We evaluated patients without known coronary artery disease (CAD) who underwent CCTA at a single center. We assessed age- and sex-specific distributions (10th, 25th, 50th, 75th, and 90th percentiles) of LV mass index. ACM, the primary endpoint, was recorded over a median period of 5.1 [interquartile range: 1.4–8.4] years. The association between LV mass and mortality risk was assessed using multivariable Cox models adjusted for age, sex, medical history, coronary artery calcium (CAC) score and CCTA stenosis.</div></div><div><h3>Results</h3><div>4187 patients (mean age: 61.9 ± 11.7, 63 % male) were included. Male sex, African American ethnicity, Hypertension, CAC>400, and smoking were independent predictors of increased LV mass index. During the median 5.1 years of study follow, 265 (6.3 %) deaths occurred. Increased LV mass index percentiles were associated with increased risk of ACM. The addition of LV mass index percentiles improved discrimination and reclassification for mortality prediction over a model with age, sex, conventional risk factors, CAC score and CCTA stenosis severity (X<sup>2</sup> improvement: 22.68, NRI: 28 %, both p < 0.001).</div></div><div><h3>Conclusion</h3><div>In a large sample of patients without known CAD who underwent CCTA, increased LV mass index provided independent and incremental prognostic value for all-cause mortality. Assessment of LV mass by CCTA, considering age and gender distribution, can be utilized clinically to identify patients with high myocardial mass.</div></div>","PeriodicalId":49039,"journal":{"name":"Journal of Cardiovascular Computed Tomography","volume":"19 1","pages":"Pages 64-71"},"PeriodicalIF":5.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How cardiac computed tomography angiography and positron emission tomography play complementary roles in a Practice's business model 心脏计算机断层扫描血管造影和正电子发射断层扫描如何在一个诊所的商业模式中发挥互补作用。

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.11.003

Renée P. Bullock-Palmer , Andrew J. Einstein , Monvadi B. Srichai

Cardiovascular imaging is fundamental and crucial for providing accurate diagnosis and guiding treatment. There are unique clinical benefits and uses of Cardiac CT as well as cardiac PET. There have been advances in cardiac PET as well as Cardiac CT which have led to novel applications. These novel applications also expand clinical practice and increase downstream referrals, testing and procedures which therefore increases business revenue. Cardiac CT adoption in practice expands business by incrementally increased use in a larger patient population. Cardiac CT does not decrease utility of other imaging modalities but ensures more appropriate use of other imaging modalities. There are upfront costs that need to be considered when adopting cardiac CT or cardiac PET. Although the upfront costs for both modalities are high and the Medicare reimbursement of cardiac CT relative to cardiac PET is lower, the ability to perform five times more cardiac CT studies per day compared with cardiac PET studies offsets the decreased reimbursement for cardiac CT. Additionally, there is a good return on investment for cardiac CT especially resulting from increased downstream testing and referrals for procedures and cardiology clinic follow up and from more efficient use of cardiac catheterization lab resources. Cardiac PET also allows for more targeted revascularization in multivessel CAD. Adopting both modalities improves patient outcomes, streamlines care, and increases downstream revenue.

心血管影像学是提供准确诊断和指导治疗的基础和关键。心脏CT和心脏PET具有独特的临床益处和用途。在心脏PET和心脏CT方面已经取得了进展，这导致了新的应用。这些新颖的应用还扩大了临床实践，增加了下游转诊、检测和程序，从而增加了业务收入。在实践中，心脏CT的采用通过在更大的患者群体中逐步增加使用来扩大业务。心脏CT不降低其他成像方式的效用，但确保更适当地使用其他成像方式。在采用心脏CT或心脏PET时，需要考虑前期成本。尽管这两种方式的前期费用都很高，而且心脏CT的医疗保险报销相对于心脏PET更低，但与心脏PET相比，每天进行5倍多的心脏CT研究的能力抵消了心脏CT报销的减少。此外，心脏CT的投资有很好的回报，特别是由于下游测试和转诊的增加，以及心导管实验室资源的更有效利用。心脏PET也允许在多血管CAD中进行更有针对性的血运重建。采用这两种模式可以改善患者的治疗效果，简化护理流程，并增加下游收入。

{"title":"How cardiac computed tomography angiography and positron emission tomography play complementary roles in a Practice's business model","authors":"Renée P. Bullock-Palmer , Andrew J. Einstein , Monvadi B. Srichai","doi":"10.1016/j.jcct.2024.11.003","DOIUrl":"10.1016/j.jcct.2024.11.003","url":null,"abstract":"<div><div>Cardiovascular imaging is fundamental and crucial for providing accurate diagnosis and guiding treatment. There are unique clinical benefits and uses of Cardiac CT as well as cardiac PET. There have been advances in cardiac PET as well as Cardiac CT which have led to novel applications. These novel applications also expand clinical practice and increase downstream referrals, testing and procedures which therefore increases business revenue. Cardiac CT adoption in practice expands business by incrementally increased use in a larger patient population. Cardiac CT does not decrease utility of other imaging modalities but ensures more appropriate use of other imaging modalities. There are upfront costs that need to be considered when adopting cardiac CT or cardiac PET. Although the upfront costs for both modalities are high and the Medicare reimbursement of cardiac CT relative to cardiac PET is lower, the ability to perform five times more cardiac CT studies per day compared with cardiac PET studies offsets the decreased reimbursement for cardiac CT. Additionally, there is a good return on investment for cardiac CT especially resulting from increased downstream testing and referrals for procedures and cardiology clinic follow up and from more efficient use of cardiac catheterization lab resources. Cardiac PET also allows for more targeted revascularization in multivessel CAD. Adopting both modalities improves patient outcomes, streamlines care, and increases downstream revenue.</div></div>","PeriodicalId":49039,"journal":{"name":"Journal of Cardiovascular Computed Tomography","volume":"19 1","pages":"Pages 139-148"},"PeriodicalIF":5.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Masthead-4C

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/S1934-5925(25)00015-2

引用次数: 0

Linking physiology to findings on invasive and non-invasive tests for the diagnosis of constrictive pericarditis 将生理学与诊断缩窄性心包炎的侵入性和非侵入性检查结果联系起来。

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.084

Jonathan Pan, Todd C. Villines

引用次数: 0

Epicardial Adipose Tissue Area And Density As Predictors Of Coronary Artery Disease

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.058

J. Erley, J. Lund, G. Adam, E. Tahir, I. Molwitz, M. Meyer

引用次数: 0

Spatial Resolution Improvements Using Photon-counting Detector Ct For the Visualization of Small Vessel Lumen: A Simulation Study

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.045

B. Szilveszter , A. Kubovje , H. Marques , B. Vattay , M. Vecsey-Nagy , M. Kolossváry , B. Konst , E. Tesselaar , M. Boussoussou , Z. Jokkel , P. Maurovich-Horvat , S. Newlander , E. McVeigh , G. Wesbey

引用次数: 0

Accuracy Of Dynamic Stress Ct Myocardial Perfusion In Patients With Suspected Non St-elevation Myocardial Infarction

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.010

M. Hinderks , O. Sliwicka , K. Salah , I. Sechopoulos , M. Brink , M. Prokop , R. Nijveldt , J. Habets , P. Damman

引用次数: 0

Establishing A Profitable New Cardiac Ct Program: A Three-tier Initiative Focused on Efficiency, Quality and Profitability

IF 5.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Computed Tomography

Pub Date : 2025-01-01 DOI: 10.1016/j.jcct.2024.12.076

H. Shahab, N. Kukar

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Cardiovascular Computed Tomography

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀